Par Pharmaceutical and Teva Pharmaceutical Industries Ltd. will not be able to launch generic versions of Pronova BioPharma Norge AS’s triglyceride-lowering treatment Lovaza until patents covering the drug expire, under a ruling from the U.S. District Court for the District of Delaware (Pronova Biopharma Norge v. Teva Pharmaceuticals USA Inc., D. Del., 1:09-cv-00286-SLR-MPT, 5/29/12).
On May 29, Judge Sue L. Robinson enjoined Par and Teva from marketing generic copies of Lovaza (omega-3-acid ethyl esters) until two Pronova patents covering Lovaza expire. The patents at issue, U.S. Patent Nos. 5,502,077 (the ‘077 patent) and 5,656,667 (the ‘667 patent), ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.